Purple Innovation Inc. (Warrants) (PRPLW): PRPL was one that got away....twice....

Play Episode

11min

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Tolu Minerals CEO reveals 8 new targets at Mt Pence and talks initial gold production at Tolukuma

Tolu Minerals Ltd CEO Iain Macpherson talked with Proactive about the company’s initial gold production at the Tolukuma Gold Mine in Papua New Guinea. While not commercial output yet, Macpherson explained that gold from commissioning demonstrates proof of concept and marks the start of larger-scale activity. The company is leveraging existing infrastructure valued at around AU$500 million, with a strategy focused on addressing previous cost pressures that led to mine closure. “The mine shut down, not because the resource ran out... but because they were faced with severe cost pressures,” Macpherson said, citing diesel dependence and lack of road access. Macpherson highlighted Tolu’s capital program and extensive exploration footprint across the broader Tolukuma structure. He detailed the utility of airborne magnetotelluric (MT) surveys, which provide deep, three-dimensional geophysical data. “It gives you a very good three-dimensional picture... and enhances target generation,” he said, noting this method’s success in similar geologies globally. The company also discussed its Mt Penck project on New Britain Island, revealing the identification of eight new porphyry targets based on the MT survey. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future content. #ToluMinerals #GoldMining #ASXTOK #PapuaNewGuinea #Tolukuma #GoldExploration #MiningStocks #PorphyryTargets #MTsurvey #JuniorMining #GoldProduction #InvestorUpdates #MiningNews

Proactive - Interviews for investors

Nexus Minerals expands Payns Find gold target

Nexus Minerals Ltd managing director Andy Tudor talked with Proactive about the latest exploration success at the Payns Find gold target, part of the company's Wallbrook Gold Project in Western Australia. Tudor described the program as “exciting” following a third air core drilling campaign that confirmed high-grade intercepts and significantly expanded the mineralised footprint. He said, “All of the attributes for a big system are here,” highlighting consistent grades of up to 5.99g/t at the extremities of a 900m by 750m target zone. The air core results revealed both supergene and fresh rock mineralisation, with around 30% of the 163 holes showing elevated geochemistry in the final metre — a strong indicator of a large underlying system. “It’s that grade in the supergene and in the fresh rock that’s got us excited,” Tudor said. He also pointed to the presence of a full suite of alteration minerals — cerussite, rutile, tourmaline, and albite — typically associated with major gold systems in the region. With the air core phase now complete, Nexus is turning to reverse circulation (RC) drill planning. Tudor confirmed that air core drilling would continue regionally, while the company prepares for a comprehensive RC program at Payns Find to test depth extensions down to 120–150m. Visit Proactive's YouTube channel for more company interviews, and don’t forget to like this video, subscribe to the channel, and hit the notification bell for future updates. #NexusMinerals #GoldExploration #ASXStocks #WallbrookProject #PaynsFind #GoldMiningWA #RCDrilling #JuniorMiners #ASXNXM #MiningNews

Followers	868
Posts	35498
Boards Moderated	17
Alias Born	03/22/2016

Volume:	-
Day Range:
Bid:	5.50
Ask:	6.00
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

PRPLW Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free